Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study examined the impact of lifestyle and medications in a young cohort with diabetes duration of less than a year and found glycaemia to be best managed by the combination of rosiglitazone and metformin, with the addition of lifestyle to metformin being no better than metformin alone161.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [161]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 3
- 10.1210/jc.82.7.2108 · doi:10.1210/jc.82.7.2108 · Paper page
- Harris SB, 2004, Can Fam Physician, 50, 425
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
Cited by
Items 401–500 of 1,014
Cheng, Y., Leu, H., Chen, T., Chen, C.-L., Kuo, C., Lee, S., & Kao, C.-L. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.09.001 · Cited by 112
Kothny, W., Shao, Q., Groop, P. ‐., & Lukashevich, V. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01634.x · Cited by 104
Diabetes and bone health: the relationship between diabetes and osteoporosis‐associated fractures
Kurra, S., & Siris, E. S. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1197 · Cited by 111
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0014-9 · Cited by 113
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Al Jobori, H., Daniele, G., Adams, J., Cersosimo, E., Solis-Herrera, C., Triplitt, C., DeFronzo, R. A., & Abdul-Ghani, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01838 · Cited by 103
Molecular determinants for the polarization of macrophage and osteoclast
Yang, D., & Wan, Y. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00754-3 · Cited by 107
New Onset Diabetes Mellitus After Solid Organ Transplantation
Pham, P. T., Pham, P. T., Lipshutz, G. S., & Wilkinson, A. H. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.07.007 · Cited by 104
The Risk of Heart Failure in Patients with Type 2 Diabetes Treated with Oral Agent Monotherapy
McAlister, F. A., Eurich, D. T., Majumdar, S. R., & Johnson, J. A. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.05.013 · Cited by 107
Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials
Mannucci, E., Monami, M., Lamanna, C., Gensini, G. F., & Marchionni, N. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00892.x · Cited by 103
Rosiglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006063.pub2 · Cited by 104
Stephens, S. B., Schisler, J. C., Hohmeier, H. E., An, J., Sun, A. Y., Pitt, G. S., & Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.011 · Cited by 89
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., García-García, H. M., van Es, G.-A., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.881003 · Cited by 103
Self-citationMetabolic Inflammation-Differential Modulation by Dietary Constituents
Lyons, C., Kennedy, E., & Roche, H. (2016) · Nutrients · doi:10.3390/nu8050247 · Cited by 104
Haider, A., Yassin, A., Doros, G., & Saad, F. (2014) · International Journal of Endocrinology · doi:10.1155/2014/683515 · Cited by 103
Smith, R. J., Nathan, D. M., Arslanian, S. A., Groop, L., Rizza, R. A., & Rotter, J. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1966 · Cited by 100
Riser Taylor, S., & Harris, K. B. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1303 · Cited by 102
Diabetes pharmacotherapy and effects on the musculoskeletal system
Kalaitzoglou, E., Fowlkes, J. L., Popescu, I., & Thrailkill, K. M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3100 · Cited by 100
The RISE Consortium (2014) · Diabetes Care · doi:10.2337/dc13-1879 · Cited by 100
Production of 7-O-Methyl Aromadendrin, a Medicinally Valuable Flavonoid, in Escherichia coli
Malla, S., Koffas, M. A. G., Kazlauskas, R. J., & Kim, B. (2011) · Applied and Environmental Microbiology · doi:10.1128/aem.06274-11 · Cited by 105
When β‐cells fail: lessons from dedifferentiation
Accili, D., Talchai, S. C., Kim-Muller, J. Y., Cinti, F., Ishida, E., Ordelheide, A., Kuo, T., Fan, J., & Son, J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12723 · Cited by 118
Medications that cause weight gain and alternatives in Canada: a narrative review
Wharton, S., Raiber, L., Serodio, K., Lee, J., & Christensen, R. A. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s171365 · Cited by 100
Dong, J. Q., Rossulek, M., Somayaji, V. R., Baltrukonis, D., Liang, Y., Hudson, K., Hernandez‐Illas, M., & Calle, R. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12676 · Cited by 100
Targeting the CNS to treat type 2 diabetes
Sandoval, D. A., Obici, S., & Seeley, R. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2874 · Cited by 110
Home, P. D., Shamanna, P., Stewart, M., Yang, F., Miller, M., Perry, C., & Carr, M. C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12414 · Cited by 101
Aprahamian, T., Bonegio, R. G., Richez, C., Yasuda, K., Chiang, L.-K., Sato, K., Walsh, K., & Rifkin, I. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.340 · Cited by 100
PPARγand Its Role in Cardiovascular Diseases
Chandra, M., Miriyala, S., & Panchatcharam, M. (2017) · PPAR Research · doi:10.1155/2017/6404638 · Cited by 113
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes
Leslie, R. D., Ronald, C. W., Franks, P. W., Nadeau, K. J., Pearson, E. R., & REDONDO, M. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00159-6 · Cited by 121
The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes
Napoli, N., Strollo, R., Paladini, A., Briganti, S., Pozzilli, P., & Epstein, S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/690783 · Cited by 110
Present status of clinical deployment of glucokinase activators
Nakamura, A., & Terauchi, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12294 · Cited by 100
β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy
Harrison, L. B., Adams-Huet, B., Raskin, P., & Lingvay, I. (2012) · Diabetes Care · doi:10.2337/dc11-2170 · Cited by 98
Bilezikian, J. P., Josse, R. G., Eastell, R., Lewiecki, E. M., Miller, C. G., Wooddell, M., Northcutt, A. R., Kravitz, B. G., Paul, G., Cobitz, A. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4018 · Cited by 99
Self-citationCardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 100
Rosiglitazone and Risk of Cancer
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-2308 · Cited by 97
Pantalone, K. M., Wells, B. J., Chagin, K. M., Ejzykowicz, F., Yu, C., Milinovich, A., Bauman, J. M., Kattan, M. W., Rajpathak, S., & Zimmerman, R. S. (2016) · Diabetes Care · doi:10.2337/dc16-0227 · Cited by 96
Precision medicine in diabetes prevention, classification and management
Xie, F., Chan, J. C., & Ma, R. C. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12830 · Cited by 97
Dual Effects of Lipid Metabolism on Osteoblast Function
Alekos, N. S., Moorer, M. C., & Riddle, R. C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.578194 · Cited by 95
Pharmacological treatment and therapeutic perspectives of metabolic syndrome
Lim, S. K., & Eckel, R. H. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9298-4 · Cited by 103
GLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 95
Mortality Rates in Trials of Subjects With Type 2 Diabetes
Barkoudah, E., Skali, H., Uno, H., Solomon, S. D., & Pfeffer, M. A. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.111.000059 · Cited by 97
Hemmingsen, B., Schroll, J. B., Wetterslev, J., Gluud, C., Vaag, A., Sonne, D. P., Lundstrom, L. H., & Almdal, T. (2014) · CMAJ Open · doi:10.9778/cmajo.20130073 · Cited by 96
Pharmacogenetics of Anti-Diabetes Drugs
DiStefano, J. K., & Watanabe, R. M. (2010) · Pharmaceuticals · doi:10.3390/ph3082610 · Cited by 110
Leiter, L. A., Carr, M. C., Stewart, M., Jones-Leone, A., Scott, R., Yang, F., & Handelsman, Y. (2014) · Diabetes Care · doi:10.2337/dc13-2855 · Cited by 95
The Metabolic Syndrome and Stroke: Potential Treatment Approaches
Arenillas, J. F., Moro, M. Á., & Dávalos, A. (2007) · Stroke · doi:10.1161/strokeaha.106.480004 · Cited by 111
Pharmacologic Treatment of Type 2 Diabetes
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014558289 · Cited by 121
Doliba, N. M., Qin, W., Najafi, H., Liu, C., Buettger, C. W., Sotiris, J., Collins, H. W., Li, C., Stanley, C. A., Wilson, D. F., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00218.2011 · Cited by 96
Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97
KCNJ11 gene E23K variant and therapeutic response to sulfonylureas
Javorský, M., Klimčáková, L., Schroner, Z., Židzik, J., Babjaková, E., Fabianová, M., Kozárová, M., Tkáčová, R., Salagovic, J., & Tkáč, I. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.10.018 · Cited by 98
Differing Effects of Metformin on Glycemic Control by Race-Ethnicity
Williams, L. K., Padhukasahasram, B., Ahmedani, B. K., Peterson, E. L., Wells, K. E., González Burchard, E., & Lanfear, D. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1539 · Cited by 95
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 102
Are targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 104
Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
Schernthaner, G., & Schernthaner-Reiter, M. H. (2018) · Diabetologia · doi:10.1007/s00125-018-4547-9 · Cited by 101
Pharmacokinetic/Pharmacodynamic Modelling in??Diabetes Mellitus
Landersdorfer, C. B., & Jusko, W. J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847070-00001 · Cited by 109
Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes
Lingvay, I., Legendre, J. L., Kaloyanova, P. F., Zhang, S., Adams-Huet, B., & Raskin, P. (2009) · Diabetes Care · doi:10.2337/dc09-0653 · Cited by 94
Bone health in diabetes: considerations for clinical management
Adami, S. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902801147 · Cited by 107
Roumie, C. L., Min, J. Y., D'Agostino McGowan, L., Presley, C., Grijalva, C. G., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Elasy, T., & Griffin, M. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005379 · Cited by 95
Pfützner, A., Paz‐Pacheco, E., Allen, E., Frederich, R., Chen, R., & for the CV181039 Investigators (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01385.x · Cited by 93
Marrow adiposity and bone: Review of clinical implications
Paccou, J., Penel, G., Chauveau, C., Cortet, B., & Hardouin, P. (2019) · Bone · doi:10.1016/j.bone.2018.02.008 · Cited by 94
Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association
Solal, A. C., Beauvais, F., & Logeart, D. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.04.001 · Cited by 99
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Hanefeld, M., Duetting, E., & Bramlage, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-135 · Cited by 93
Incretin Effects on β-Cell Function, Replication, and Mass
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s230 · Cited by 92
“Because most current therapeutic options address the impaired glucose action or stimulate insulin secretion rather than the declining b-cell function, the ongoing decline in b-cell function leads to eventual failure of most antidiabetic therapies (3,4).”
BackgroundRathmann, W., Kostev, K., Gruenberger, J. B., Dworak, M., Bader, G., & Giani, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01674.x · Cited by 93
A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
Solomon, D. H., Cadarette, S. M., Choudhry, N. K., Canning, C., Levin, R., & Stürmer, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2157 · Cited by 93
Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus
Jellinger, P. S., Davidson, J. A., Blonde, L., EINHORN, D. F., Grunberger, G., Handelsman, Y., Hellman, R., Lebovitz, H. E., Levy, P., & Roberts, V. L. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.260 · Cited by 104
Type 2 diabetes, related conditions, in relation and dementia: An opportunity for prevention?
Luchsinger, J. A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091687 · Cited by 91
DPP-4 inhibitors: What may be the clinical differentiators?
Gerich, J. E. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.07.006 · Cited by 100
Edwards, C., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.007 · Cited by 121
Pajvani, U. B., & Accili, D. (2015) · Diabetologia · doi:10.1007/s00125-015-3722-5 · Cited by 97
Dopamine-Mediated Autocrine Inhibitory Circuit Regulating Human Insulin Secretion in Vitro
Simpson, N., Maffei, A., Freeby, M., Burroughs, S., Freyberg, Z., Javitch, J., Leibel, R. L., & Harris, P. E. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1101 · Cited by 86
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H.-U., Joost, H.-G., Kellerer, M., Kloos, C., Kunt, T., Nauck, M., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 91
The pharmacogenetics of metformin
Florez, J. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4335-y · Cited by 90
Grün, F. (2010) · Current Opinion in Endocrinology, Diabetes and Obesity · doi:10.1097/med.0b013e32833ddea0 · Cited by 91
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
Cho, Y. M., & Kieffer, T. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1986-3 · Cited by 98
Morgan, C. L., Poole, C. D., Evans, M., Barnett, A. H., Jenkins-Jones, S., & Currie, C. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3034 · Cited by 89
Arbuckle, R. A., Humphrey, L., Vardeva, K., Arondekar, B. V., Viala-Danten, M., Scott, J. A., & Snoek, F. J. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00571.x · Cited by 91
Steinberg, B. A., Bhatt, D. L., Mehta, S. R., Poole-Wilson, P. A., O’Hagan, P., Montalescot, G., Ballantyne, C. M., & Cannon, C. P. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.05.020 · Cited by 92
The rise and fall of rosiglitazone
Nissen, S. E. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq016 · Cited by 90
Actos Now for the prevention of diabetes (ACT NOW) study
DeFronzo, R. A., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R., et al. (2009) · BMC Endocrine Disorders · doi:10.1186/1472-6823-9-17 · Cited by 89
“Pioglitazone and other thiazolidinediones have been shown both to enhance muscle/hepatic/adipocyte insulin sensitivity [23-26] and to improve beta cell function [16,18,27,28].”
Complications and comorbidities of T2DM in adolescents: findings from the TODAY clinical trial
Tryggestad, J. B., & Willi, S. M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.10.009 · Cited by 97
Current Status of Islet Cell Replacement and Regeneration Therapy
Halban, P. A., German, M. S., Kahn, S. E., & Weir, G. C. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1819 · Cited by 106
Self-citationAntidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS
Akimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., Inoue, N., Ohshima, S., & Kobayashi, D. (2020) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317519899546 · Cited by 89
Drug-Induced Hypoglycaemia: An Update
Salem, C. B., Fathallah, N., Hmouda, H., & Bouraoui, K. (2010) · Drug Safety · doi:10.2165/11538290-000000000-00000 · Cited by 97
Idris, I., Warren, G., & Donnelly, R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.1938 · Cited by 88
Thiazolidinediones Induce Osteocyte Apoptosis by a G Protein-coupled Receptor 40-dependent Mechanism
Mieczkowska, A., Baslé, M. F., Chappard, D., & Mabilleau, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.324814 · Cited by 97
Vischer, U. M., Bauduceau, B., Bourdel‐Marchasson, I., Blicklé, J. F., Constans, T., Fagot‐Campagna, A., Kaloustian, E., Lassman-Vague, V., Lecomte, P., Simon, D., et al. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.02.003 · Cited by 98
Borges, J. L. C., Bilezikian, J. P., Jones‐Leone, A. R., Acusta, A. P., Ambery, P. D., Nino, A. J., Grosse, M., Fitzpatrick, L. A., & Cobitz, A. R. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01461.x · Cited by 90
Protection of pancreatic beta-cells: Is it feasible?
Bonora, E. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.05.004 · Cited by 108
Nuclear Receptors in Bone Physiology and Diseases
Imai, Y., Youn, M.-Y., Inoue, K., Takada, I., Kouzmenko, A., & Kato, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2012 · Cited by 88
Precision medicine in diabetes: an opportunity for clinical translation
Merino, J., & Florez, J. C. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13588 · Cited by 96
Hannon, T. S., Kahn, S. E., Utzschneider, K. M., Buchanan, T. A., Nadeau, K. J., Zeitler, P. S., Ehrmann, D. A., Arslanian, S. A., Caprio, S., Edelstein, S. L., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13005 · Cited by 87
Self-citationBergmark, B. A., Bhatt, D. L., McGuire, D. K., Cahn, A., Mosenzon, O., Steg, P. G., Im, K., Kanevsky, E., Gurmu, Y., Raz, I., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040144 · Cited by 88
Mohan, V., Khunti, K., Chan, S. P., Filho, F. F., Tran, N. Q., Ramaiya, K. L., Joshi, S., Mithal, A., Mbaye, M. N., Nicodemus, N. A., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00733-9 · Cited by 113
Duong, J. K., Furlong, T. J., Roberts, D. M., Graham, G. G., Greenfield, J. R., Williams, K. M., & Day, R. O. (2013) · Drug Safety · doi:10.1007/s40264-013-0038-6 · Cited by 98
The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK
Tahrani, A. A., Ball, A., Shepherd, L., Rahim, A., Jones, A. F., & Bates, A. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02221.x · Cited by 90
Thiazolidinedione‐induced skeletal fragility – mechanisms and implications
Grey, A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00931.x · Cited by 90
Del Prato, S., Camisasca, R., Wilson, C., & Fleck, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12377 · Cited by 87
Diabetes mellitus: new challenges and innovative therapies
Sena, C. M., Bento, C. F., Pereira, P., & Seiça, R. M. F. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0010-9 · Cited by 105
Kohro, T., Yamazaki, T., Sato, H., Harada, K., Ohe, K., Komuro, I., & Nagai, R. (2013) · International Heart Journal · doi:10.1536/ihj.54.93 · Cited by 88
The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression
Aubert, G., Mansuy‐Aubert, V., Voirol, M., Pellerin, L., & Pralong, F. P. (2010) · Metabolism · doi:10.1016/j.metabol.2010.02.007 · Cited by 95
Balas, B., Belfort, R., Harrison, S. A., Darland, C., Finch, J., Schenker, S., Gastaldelli, A., & Cusi, K. J. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.013 · Cited by 93
Erion, D. M., Park, H., & Lee, H. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.3.268 · Cited by 101
Metadata
- Authors
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., & Viberti, G.
- Affiliations
- University of Washington (US)
- The University of Texas at San Antonio Health Science Center (US)
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- University of London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2427-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081276121
- Cited by
- 2,962
- References
- 37
- Citations by year
- 2026: 48 · 2025: 64 · 2024: 77 · 2023: 66 · 2022: 88 · 2021: 98 · 2020: 120 · 2019: 102 · 2018: 120 · 2017: 139 · 2016: 163 · 2015: 158 · 2014: 181 · 2013: 202 · 2012: 180
- FWCI
- 163.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, rosiglitazone, metformin, glibenclamide, thiazolidinediones, glycemic control, fasting blood glucose, HbA1c, insulin sensitivity, beta-cell function, cardiovascular events, congestive heart failure, hypoglycemia, weight gain, edema, gastrointestinal adverse effects, drug selection
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glyburide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Weight Gain, Proportional Hazards Models, Treatment Outcome, Thiazolidinediones, Waist-Hip Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.